Back to Ovarian Cancer
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT00227721

NCT00227721
Completed Phase 2

Who may be able to join

Who might be able to join this trial:

  • You have been diagnosed with ovarian cancer or peritoneal cavity cancer that was confirmed by a tissue sample (biopsy)
  • Your cancer came back or stopped responding after your first treatment, which must have included a platinum-based chemotherapy drug
  • Your cancer may have either responded to platinum treatment initially (platinum-sensitive) or stopped responding within 6 months of finishing it (platinum-resistant)
  • Your cancer can be measured or tracked — either through scans or through a blood marker called CA 125 that has risen significantly over time
  • You are 18 years of age or older
  • You are reasonably active and able to care for yourself (confirm with trial site)
  • Your blood counts are at acceptable levels — including white blood cells, neutrophils, platelets, and hemoglobin
  • Your liver is functioning within acceptable ranges, based on blood tests
  • Your kidneys are functioning well enough, based on blood tests
  • You have only received one prior chemotherapy treatment course for this cancer
  • It has been at least 4 weeks since any previous radiotherapy and you have recovered from it

Who may not be able to join:

  • You are pregnant, breastfeeding, or not willing to use effective contraception if you could become pregnant
  • You have significant nerve damage or numbness/tingling in your hands or feet beyond a mild level
  • You have been diagnosed with another cancer in the past 2 years (exceptions may apply for certain skin cancers or early-stage cervical changes — confirm with trial site)
  • You have had a heart attack in the past 3 months
  • You have heart failure or certain types of irregular heart rhythm
  • You have previously had a severe allergic reaction to medications containing a substance called polysorbate 80 (an ingredient used in some drug formulations)
  • You have previously received gemcitabine or docetaxel chemotherapy
  • You have received more than one course of chemotherapy for this cancer
  • You are currently taking part in another clinical trial or receiving any other experimental treatment for this cancer
  • You are currently receiving any other treatment for this cancer at the same time

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 2
Sponsor
Robert Morris
Registry
clinicaltrials_gov
Start date
1 February 2004
Est. completion
1 June 2011

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Response Rate to the Combination of Gemcitabine and Docetaxel in Patients With Platinum Sensitive and Resistant Epithelial Ovarian or Peritoneal Cancer.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov